EGFR and non-small cell lung carcinoma: These data are a part of a clinical trial, which is a multicenter observational study with both retrospective and prospective data collection to describe the effectiveness and safety of sequential dacomitinib and third‐generation EGFR TKIs used in patients with EGFR‐mutation‐positive NSCLC with T790M‐acquired resistance in a clinical practice setting.